- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03008785
Effect of Isoflavone Supplementation Associated With Physical Exercise in the Health Parameters of Postmenopausal Women
February 19, 2019 updated by: Juliene Gonçalves Costa, Federal University of Uberlandia
Effect of Isoflavone Supplementation Associated With Physical Exercise on Blood Pressure, Lipic and Inflamatory Profile, Body Composition and Hydratation and Climacteric Symptoms in Postmenopausal Women
This study evaluate if 10 weeks of mixed exercise combined with isoflavones could have greater effects on climacteric symptoms, body composition and hydratation, lipidic and inflamatory profile than exercise alone in postmenopausal women.
the participants will be randomly assigned to the group: placebo and exercise or 100mg of isoflavone and exercise.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Several endocrine metabolic changes occur during the climacteric period, due to the lack of estrogen and also by the aging process and some studies show that ingestion of isoflavones by postmenopausal women may have benefits.
Theoretically the isoflavone potentiate the effects obtained during exercise
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minas Gerais
-
Uberlandia, Minas Gerais, Brazil, 38400-678
- Guilherme Morais Puga
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Healthy postmenopausal woman
- to be able to practice exercises on treadmill and weight exercises
- without physical complications that prevent the execution of physical exercises
- have no history of cardiovascular disease, diabetes, renal pathologies or hypertension
Exclusion Criteria:
- smokers
- use hormone therapy or isoflavone
- use drugs that interfere with lipid and antihypertensive metabolism
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: group isoflavone and exercise
The isoflavone group received daily 100mg of isoflavones.
|
Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
|
|
Experimental: group placebo and exercise
The placebo group received 100mg containing starch of corn.
|
The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
Daily supplementation in 1 capsule per day containing starch of corn.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in blood pressure
Time Frame: Change in blood pressure in 10 weeks intervention
|
Evaluate change in blood pressure through ambulatory 24-hour blood pressure monitoring used before the begin of intervention and after 10 weeks.
|
Change in blood pressure in 10 weeks intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Climateric Symptoms (Kupperman-Blatt Index)
Time Frame: before and after 10 weeks
|
Evaluate the intensity of climateric symptoms using the Kupperman-Blatt Index questionnaire.
Consists of 11 questions in which the symptoms are given numerical values according to their intensity .
|
before and after 10 weeks
|
|
Climateric Symptoms (Cervantes Scale)
Time Frame: before the begin the intervention and after 10 weeks
|
Evaluate the intensity of climateric symptoms using the Cervantes Scale questionnaire.
Composed of 31 questions distributed in four domains and 6 possibilities of answer.
|
before the begin the intervention and after 10 weeks
|
|
Climateric Symptoms (Menopause Rating Scale)
Time Frame: before and after 10 weeks
|
Evaluate the intensity of climateric symptoms using the Menopause Rating Scale questionnaire.
Composed of eleven questions, with five possible answers, Symptoms divided into somatovegetative, psychological and urogenital domains may be classified as absent, mild, moderate, severe and very severe.
With a general score ranging from 0 to 55 points
|
before and after 10 weeks
|
|
Lipid profile (enzymatic colorimetric method)
Time Frame: before and after 10 weeks
|
The concentrations in mg/dL of total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol and uric acid will be made through the enzymatic colorimetric method.
The glucose will be analyzed by the enzymatic method and the glycated hemoglobin A1c by the turbidimetry method.
|
before and after 10 weeks
|
|
Human cytokines (Flow Cytometry)
Time Frame: before and after 10 weeks
|
Measurement in pg/mL of the production of human cytokines (IL-8, IL-1β, IL-6, TNF ( tumor necrosis factor), IL-10 and IL-12p70) in serum samples will be performed by the flow cytometry (FACSCantoII BDTM) Human Inflammatory Cytokines Kit "(BD ™ Cytometric Bead Array (CBA), BD Biosciences, San Jose, CA, USA) according to the manufacturer's instructions.
|
before and after 10 weeks
|
|
Antioxidant capacity
Time Frame: before and after 10 weeks
|
The total antioxidant capacity will be evaluated in plasma and saliva using the FRAP (Ferric-Absorbing Ability of Plasma) methodology (Benzie and Strain, 1999).
|
before and after 10 weeks
|
|
Total protein
Time Frame: before and after 10 weeks
|
The determination of the total salivary and plasma protein will be performed by the Bradfort method (Bradford, 1976) adapted for microplate
|
before and after 10 weeks
|
|
Body Composition
Time Frame: before and after 10 weeks
|
Bioelectrical impedance (Biodynamics, model 450c, EUA) will be used to determine absolute and relative extracellular mass and body cell mass.
|
before and after 10 weeks
|
|
Phase Angle
Time Frame: before and after 10 weeks
|
Phase angle in degrees (o) was calculated using the equation (Reactance/Resistance) *(180/л) using a values obtained on bioelectrical impedance (Biodynamics, model 450c, EUA) |
before and after 10 weeks
|
|
Oxidative stress (SOD, Catalase and TBARS activity)
Time Frame: before and after 10 weeks
|
The enzyme superoxide dismutase (SOD) will be dosed from the auto oxidation capacity of pyrogallol, a process dependent on the superoxide radical (Fernandes et al., 2011). .
Catalase activity in saliva will be determined based on the decrease in absorbance of hydrogen peroxide (H2O2) (Aebi, 1984).
Thiobarbituric acid reactive substances (TBARS) will be detected by the Yagi method (Yagi, 1998).
|
before and after 10 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Guilherme Puga, PhD, Federal University of Uberlândia
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Acharjee S, Zhou JR, Elajami TK, Welty FK. Effect of soy nuts and equol status on blood pressure, lipids and inflammation in postmenopausal women stratified by metabolic syndrome status. Metabolism. 2015 Feb;64(2):236-43. doi: 10.1016/j.metabol.2014.09.005. Epub 2014 Oct 5.
- Lebon J, Riesco E, Tessier D, Dionne IJ. Additive effects of isoflavones and exercise training on inflammatory cytokines and body composition in overweight and obese postmenopausal women: a randomized controlled trial. Menopause. 2014 Aug;21(8):869-75. doi: 10.1097/GME.0000000000000177.
- Barbosa CD, Costa JG, Giolo JS, Rossato LT, Nahas PC, Mariano IM, Batista JP, Puga GM, de Oliveira EP. Isoflavone supplementation plus combined aerobic and resistance exercise do not change phase angle values in postmenopausal women: A randomized placebo-controlled clinical trial. Exp Gerontol. 2019 Mar;117:31-37. doi: 10.1016/j.exger.2018.08.007. Epub 2018 Sep 1.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2015
Primary Completion (Actual)
July 1, 2016
Study Completion (Actual)
December 1, 2016
Study Registration Dates
First Submitted
December 28, 2016
First Submitted That Met QC Criteria
December 29, 2016
First Posted (Estimate)
January 2, 2017
Study Record Updates
Last Update Posted (Actual)
February 20, 2019
Last Update Submitted That Met QC Criteria
February 19, 2019
Last Verified
February 1, 2019
More Information
Terms related to this study
Other Study ID Numbers
- CAAE: 40622414.9.0000.5152
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bloodpressure
-
University Hospital, Gentofte, CopenhagenRecruitingBloodpressureDenmark
-
University Medical Center GroningenCompleted
-
Dr. Robert TanzolaCompleted
-
University Medical Center GroningenCompleted
-
Universitätsklinikum Hamburg-EppendorfCompletedFluid Overload | Bloodpressure | Volume Overload | Hemodynamic Rebound
-
University of California, San FranciscoTerminatedPilot to Examine Risk and Feasibility of Remote Management of BP From CKD Through ESRD (PERFORMANCE)Hypertension | Chronic Kidney Disease | BloodpressureUnited States
Clinical Trials on isoflavone
-
Seoul National University HospitalCompletedAgeing | Photo-agingKorea, Republic of
-
University of East AngliaCompletedCardiovascular Disease Risk ReductionUnited Kingdom
-
National Nutrition and Food Technology InstituteCompleted
-
National Nutrition and Food Technology InstituteUnknownPeritoneal Dialysis PatientsIran, Islamic Republic of
-
National Cancer Institute (NCI)CompletedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Oral Cavity Verrucous Carcinoma | Tongue... and other conditionsUnited States
-
National Health Research Institutes, TaiwanGenovate Biotechnology Co., Ltd.,; Taiwan Biotech Co., Ltd.Unknown
-
Johns Hopkins UniversityNational Cancer Institute (NCI); Physicians LaboratoriesCompleted
-
Federal University of UberlandiaCompleted
-
Beth Israel Deaconess Medical CenterNichimo - Tokyo, JapanCompleted
-
Wageningen UniversityCompleted